Photo: ajay_suresh / Wikimedia Commons, CC BY 4.0, cropped
Johnson & Johnson Beat Earnings and Raised Its Outlook. Why Did the Stock Fall 6%?
- J&J's adjusted earnings were $2.59 a share on revenue of about $25.4 billion, beating forecasts. It raised its full-year profit outlook.
- MedTech sales rose just 2.5% to about $8.6 billion, missing the $8.71 billion forecast. Sales outside the US were roughly flat. It was the second straight quarterly miss.
- Drug sales (Innovative Medicine) rose 7.7% to about $16.8 billion.
- Shares fell more than 6% on October 13. Boston Scientific fell nearly 3% and Intuitive Surgical about 2% in sympathy.
- Reported profit was much lower because of about $7 billion of charges, including a proposed talc settlement. J&J is reportedly leaning toward spinning off its orthopedics business.
What happened
Johnson & Johnson reported third-quarter results before the market opened on Tuesday, October 13. On paper, it was a good quarter:
- Adjusted earnings of $2.59 a share, above forecasts
- Revenue of about $25.4 billion
- A higher full-year profit outlook
The stock fell more than 6% anyway.
The problem: medical devices
J&J has two businesses. Innovative Medicine makes prescription drugs. MedTech makes medical devices, from heart catheters to hip implants to contact lenses.
| Division | Q3 2026 sales | Growth | vs forecast |
|---|---|---|---|
| Innovative Medicine (drugs) | about $16.8 billion | +7.7% | Strong |
| MedTech (devices) | about $8.6 billion | +2.5% | Missed ($8.71B expected) |
Sources: J&J results and CNBC, October 13, 2026.
MedTech sales outside the US were roughly flat. It was the second quarter in a row the division missed.
J&J's MedTech chief, Tim Schmid, admitted results were below the company's own standard and below what it had told investors to expect.
Why devices are struggling
J&J named three headwinds, all hitting international sales:
- The Middle East conflict, disrupting sales in the region.
- Austerity in Europe, as governments squeeze health budgets.
- Pricing pressure in China, where bulk government purchasing pushes prices down.
Growth came from heart-rhythm products, Shockwave (a heart-device company J&J bought in 2024), contact lenses and trauma products.
Why one division can sink a good quarter
Investors pay for future growth. The drug business is doing well, but drugs face patent expirations that eventually cut sales. J&J has pitched MedTech as its second growth engine. Two misses in a row raise doubts about that story.
Other device stocks fell in sympathy: Boston Scientific dropped nearly 3% and Intuitive Surgical about 2%. A JPMorgan analyst cautioned that J&J's problems may not apply to the whole sector.
The other headlines
- About $7 billion of charges, including a proposed settlement of talc lawsuits and deal costs, cut reported profit sharply. These are one-time items, which is why companies also report "adjusted" earnings.
- Orthopedics spin-off. J&J is reportedly leaning toward spinning off its hip and knee implant business. A spin-off gives shareholders new shares in the separate company.
What it means for investors
Beat-and-raise isn't always enough. The market reacts to the part of the story that changed. Here, that was MedTech. Our guide to reading an earnings report explains how to spot the line that matters.
Dividend investors: J&J has raised its dividend every year for more than 60 years. Nothing in this report threatens that. A lower share price also means a higher dividend yield. See what a dividend is.
Healthcare is busy: Deals keep coming in the sector, such as Viatris buying Pacira.
What to watch next
- Fourth-quarter MedTech sales. Management said it is focused on improving them.
- The talc settlement, which still needs approval.
- Any formal spin-off announcement for orthopedics.
Frequently asked questions
Why did Johnson & Johnson stock fall after earnings?
J&J's shares fell more than 6% on October 13, 2026 because its MedTech (medical device) division grew only 2.5% to about $8.6 billion, missing analyst forecasts of about $8.71 billion for the second straight quarter. Investors focused on that weakness even though overall earnings beat and guidance was raised.
What were J&J's Q3 2026 earnings?
Johnson & Johnson reported adjusted earnings of $2.59 per share on revenue of about $25.4 billion for the third quarter of 2026, ahead of forecasts. Drug sales rose 7.7% to about $16.8 billion. Reported net earnings were much lower because of about $7 billion in charges, including a proposed talc settlement and deal costs.
Why are J&J's medical device sales weak?
The company pointed to the Middle East conflict, austerity measures in European health systems and pricing pressure in China, which hit international sales harder. Growth came from heart-rhythm (electrophysiology) products, Shockwave, contact lenses and trauma products.
Is J&J spinning off its orthopedics business?
Reports say J&J is leaning toward spinning off its orthopedics business, which makes hip and knee implants. No final decision had been announced as of October 13, 2026.
Is Johnson & Johnson still a good dividend stock?
J&J has raised its dividend every year for more than six decades, and its drug business is growing. The stock's fall reflects concern about one division, not the dividend. Whether it fits your portfolio depends on your goals; this article is educational, not advice.
Primary sources
- Johnson & Johnson — Q3 2026 results (Form 8-K, Exhibit 99.1)
- CNBC — J&J posts weak medical device sales, shares fall (Oct. 13, 2026)
- Yahoo Finance — Johnson & Johnson beats third-quarter estimates and raises 2026 outlook
- Quartz — Johnson & Johnson raises profit guidance in Q3 2026 earnings
- GuruFocus — J&J Q3 earnings beat but shares drop on MedTech revenue miss
Data & disclaimer: This article is for educational purposes only and is not financial or investment advice. Figures reflect data available as of Oct 14, 2026, and conditions change — always confirm current pricing, rates and rules with the provider before you act. Written by Elizabeta Dimoska. See our editorial standards and disclosure.
Comments